Free Trial

Silverback Therapeutics (NASDAQ:SBTX) Trading Down 1.9% - Here's Why

Silverback Therapeutics logo with Medical background

Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report) dropped 1.9% during mid-day trading on Wednesday . The stock traded as low as $17.19 and last traded at $17.56. Approximately 972,931 shares were traded during trading, an increase of 188% from the average daily volume of 337,931 shares. The stock had previously closed at $17.90.

Silverback Therapeutics Stock Up 2.7%

The business has a fifty day moving average price of $15.40 and a 200-day moving average price of $13.54. The company has a market cap of $661.66 million, a P/E ratio of -7.58 and a beta of 0.60.

Silverback Therapeutics Company Profile

(Get Free Report)

Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.

Further Reading

Should You Invest $1,000 in Silverback Therapeutics Right Now?

Before you consider Silverback Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silverback Therapeutics wasn't on the list.

While Silverback Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines